Patients' Perception of the Impact of Innovation on Hemophilia Care Management Organization: A Qualitative Study Protocol (INNOVHEMO Study).
care pathway
hemophilia
organizational aspect
patient experience data
qualitative research
therapeutic innovation
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
05
2021
accepted:
21
07
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
27
8
2021
Statut:
epublish
Résumé
New therapies provide a favorable evolution in the care management of persons with hemophilia. However, the impact of these new therapies on patient care organization remains to be determined. A qualitative study will be implemented to analyze patients' perception regarding the impact of innovation on the organization of their care management. Secondary objectives will include refining specific factors related to persons with hemophilia (barriers or facilitators, especially the place of treatment) to consider within an organizational impact analysis. Semi-structured individual interviews will be conducted via videoconferencing or by phone by two researchers using an interview guide. Participants will be recruited from the Rhône-Alpes region, in France. Physicians from two hemophilia treatment centers will identify eligible patients. Moreover, a call for volunteers will be launched by the Rhône-Alpes committee of the French hemophilia association. Interviews will be conducted with adult patients, adolescent patients or parents of a minor with hemophilia regularly treated prophylactically or on demand. Data analysis will be performed with NVivo The INNOVHEMO study is an original study analyzing the way patients perceive the impact of an innovation on their care management organization. The resulting patient-specific factors, identified as barriers or facilitators, will need to be integrated into a more comprehensive analysis of the impact of innovation on care management organization.
Sections du résumé
BACKGROUND
BACKGROUND
New therapies provide a favorable evolution in the care management of persons with hemophilia. However, the impact of these new therapies on patient care organization remains to be determined. A qualitative study will be implemented to analyze patients' perception regarding the impact of innovation on the organization of their care management. Secondary objectives will include refining specific factors related to persons with hemophilia (barriers or facilitators, especially the place of treatment) to consider within an organizational impact analysis.
PATIENTS AND METHODS
METHODS
Semi-structured individual interviews will be conducted via videoconferencing or by phone by two researchers using an interview guide. Participants will be recruited from the Rhône-Alpes region, in France. Physicians from two hemophilia treatment centers will identify eligible patients. Moreover, a call for volunteers will be launched by the Rhône-Alpes committee of the French hemophilia association. Interviews will be conducted with adult patients, adolescent patients or parents of a minor with hemophilia regularly treated prophylactically or on demand. Data analysis will be performed with NVivo
DISCUSSION
CONCLUSIONS
The INNOVHEMO study is an original study analyzing the way patients perceive the impact of an innovation on their care management organization. The resulting patient-specific factors, identified as barriers or facilitators, will need to be integrated into a more comprehensive analysis of the impact of innovation on care management organization.
Identifiants
pubmed: 34434044
doi: 10.2147/PPA.S322531
pii: 322531
pmc: PMC8380624
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1807-1815Informations de copyright
© 2021 Beny et al.
Déclaration de conflit d'intérêts
Mr Benjamin du Sartz de Vigneulles reports being an employee until march 2019, Oncology Department for Pierre Fabre Laboratories. The authors report no other conflicts or competing interests in this work.
Références
Blood Rev. 2020 Jan;39:100618
pubmed: 31676141
Curr Hematol Rep. 2003 Sep;2(5):395-401
pubmed: 12932311
Lancet. 2021 Feb 13;397(10274):630-640
pubmed: 33460559
J Clin Nurs. 2019 Nov;28(21-22):4077-4086
pubmed: 31328340
Haemophilia. 2018 May;24 Suppl 6:15-21
pubmed: 29878661
Can Fam Physician. 1998 Nov;44:2453-8
pubmed: 9839063
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Value Health. 2020 Jul;23(7):862-869
pubmed: 32762987
Br J Haematol. 2006 Jun;133(6):591-605
pubmed: 16704433
Mol Ther. 2020 Apr 8;28(4):997-1015
pubmed: 31843450
Patient. 2020 Apr;13(2):201-210
pubmed: 31691206
Ann Hematol. 1991 Feb;62(1):5-15
pubmed: 1903310
Hamostaseologie. 2020 Aug;40(3):311-321
pubmed: 32726826
Haemophilia. 2021 Jan;27 Suppl 1:8-16
pubmed: 33522654
Haemophilia. 2021 Jan;27(1):129-136
pubmed: 33161616
Haemophilia. 2016 Jul;22 Suppl 5:15-9
pubmed: 27405670
NPJ Prim Care Respir Med. 2019 Apr 2;29(1):9
pubmed: 30940806
Blood Rev. 2021 Mar;46:100737
pubmed: 32739122
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
Haemophilia. 2019 Sep;25(5):814-820
pubmed: 31365176
Lancet. 2016 Jul 9;388(10040):187-97
pubmed: 26897598
Orphanet J Rare Dis. 2012 May 02;7:24
pubmed: 22551339
Haemophilia. 2017 May;23(3):e180-e187
pubmed: 28393468
Haemophilia. 2021 Mar;27(2):221-228
pubmed: 33506955
N Engl J Med. 2001 Jun 7;344(23):1773-9
pubmed: 11396445
Transfus Apher Sci. 2019 Oct;58(5):565-568
pubmed: 31427262
Br J Haematol. 2007 Aug;138(3):305-15
pubmed: 17614818
PLoS One. 2020 Apr 15;15(4):e0231571
pubmed: 32294125
Lancet. 2007 Aug 4;370(9585):439-48
pubmed: 17679021
Haemophilia. 2013 Jul;19(4):475-80
pubmed: 23777531
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Am J Hematol. 2021 Jan;96(1):128-144
pubmed: 33064330
Haemophilia. 2019 Jul;25(4):640-650
pubmed: 31115094
Patient. 2019 Dec;12(6):611-619
pubmed: 31313270
Haemophilia. 2019 Nov;25(6):938-945
pubmed: 31531924
Hematology. 2019 Dec;24(1):737-741
pubmed: 31711380
J Am Pharm Assoc (2003). 2019 Nov - Dec;59(6):797-803
pubmed: 31405805
Haemophilia. 2017 Jul;23(4):556-565
pubmed: 28419637
Int J Clin Pharm. 2016 Feb;38(1):61-9
pubmed: 26474860
Haemophilia. 2019 May;25(3):382-391
pubmed: 31016855